Sihuan Pharmaceutical Launched an Equity Incentive Plan to Inject New Impetus for the Company’s...

Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") announced that on 26 August 2020,...

Jacobson Pharma Collaborates with Fosun Pharma Group to Supply Potentially 10 Million Doses of...

Jacobson Pharma Corporation Limited ("Jacobson Pharma" or "the Group"; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale...

Universal Medical Announced its 2020 Interim Results

Maintained Steady Financial Performance under COVID-19 Pandemic Proceed with Hospital Group Business The board (the "Board") of directors (the "Directors") of Genertec Universal Medical Group Company...

Novotech the Asia-Pacific CRO Leader – Awarded ‘2020 Frost & Sullivan Asia-Pacific CRO Company...

Novotech, the largest biotech specialist CRO in the Asia-Pacific region, was awarded the '2020 Frost & Sullivan Asia-Pacific CRO Company of the Year' in...

Sihuan Pharmaceutical Announces 2020 Interim Results

Revenue and Profit Attributable to Owners of the Company from Continuing Operations are RMB1,054.5 million and RMB170.5 million, respectively; Multiple R&D and Production Platforms as...

Ivermectin Triple Therapy Protocol for COVID-19 Released to Australian GPs for Infected Elderly and...

Triple therapy specialist Professor Thomas Borody, famous for curing peptic ulcers using a triple antibiotic therapy saving millions of lives, today released the COVID-19...

AIM ImmunoTech提供2020年第二季度業務更新並報告COVID-19和癌症試驗進展

免疫藥物公司AIM ImmunoTech(NYSE- American 交易代碼: AIM) 是一家致力於研究治療免疫疾病,病毒性疾病和多種類型癌症的療法的免疫藥物公司,今天提供了截至2020年6月30日的第二季度業務和臨床前/臨床更新。 2020年第二季度財務摘要: - 截至2020年6月30日,AIM的現金,現金等價物和有價證券為4030萬美元,而截至2019年12月31日為880萬美元。 - 截至2020年6月30日的第二季度的研發費用為146萬美元,而截至2019年6月30日的第二季度的研發費用為110萬美元。 - 截至2020年6月30日的第二季度的一般和行政支出為172萬美元,而截至2019年6月30日的第二季度的194萬美元。 公司的2020年6月30日完整財務業績包含在於2020年8月14日提交給美國證券交易委員會的10-Q表內,該表格可從www.sec.gov和公司網站上獲得。 “ AIM致力於滿足COVID-19和癌症等關鍵未滿足的醫療需求的極其重要且具有開創性的臨床前和臨床研究,這為我們在廣闊的潛在市場中提供了“多重目標”。根據這些多種表現,AIM支持這些試驗的策略是最大限度地增加直接授予臨床站點的第三方,非稀釋性資金,是我們在許多試驗中均已完成的。此外,截至2020年6月30日,我們的資產負債表上有超過4,000萬美元的現金,現金等價物和有價證券。因此,我們相信,我們非常有能力執行未來的戰略,反過來,我們預計將為股東帶來可觀的價值。” AIM首席執行官Thomas K. Equels說。 COVID-19常規更新: - 在FDA於2020年5月11日批准IND後,AIM於2020年7月6日與Roswell Park 綜合癌症中心簽署了一項臨床試驗協議,以支持Roswell Park Ampligen與乾擾素alfa-2b聯合治療的1 / 2a期臨床試驗在患有COVID-19的癌症患者中,該疾病由SARS-CoV-2引起。該試驗有望很快開始患者入組。 - AIM與日本國立傳染病研究所和 Shionogi 公司簽署了三邊材料轉移和研究協議, Shionogi...

Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel...

- Investigational first-in-class glucokinase activator, with a novel mode of action, focused on fixing the glucose sensor and restoring glucose homeostasis for Type 2...

QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma

MSD collaboration to investigate QBiotics' lead molecule tigilanol tiglate in combination with KEYTRUDA(R) (pembrolizumab) Tigilanol tiglate is a novel, small molecule being developed...

China Medical System Holdings Limited 2020 Interim Results Announcement

Turnover (excl. the effect of "two-invoice system") up 4.6% to RMB3,557.1 Million; Profit up 11.4% to RMB1,300.5 Million; Continuous Expansion of Innovative Pipeline; Positive Progress Made in...

Epazz Engages PCAOB Auditor in Order to Uplist to the OTCQB; Releases Contact Tracing...

Epazz Engages PCAOB Auditor in Order to Uplist to the OTCQB; Releases Contact Tracing Update to DeskFlex for Covid-19 Back to School Epazz Inc. DeskFlex...

Milestone for Biowin’s Rapid COVID-19 Nucleic Acid Detector

Nasdaq-listed Shineco, Inc to acquire 73.7% stake in Changzhou Biowin Pharmaceutical Changzhou Biowin Pharmaceutical Co., Ltd. ("Biowin"), a Chinese biotech company focusing on diagnostic product...

Novotech荣膺全球职场文化权威机构认证的“2020 年最佳职场”称号

亚太地区领先的生物技术委托研究机构 CRO Novotech被领先的职场文化机构卓越职场(R)研究所 (The Great Place to Work(R) Institute) 认证为“2020 年最佳职场”。这项殊荣是在通过包括文化评估和员工调查在内的全面评估之后授予的。 在获得认证后,Novotech首席执行官 John Moller 博士说: “这项最佳职场奖对我们而言举足轻重,它是对我们在人员和文化议程上所做的巨大投资的认可。Novotech团队在为数众多的不同地区、文化和语言环境中工作,为我们的生物技术客户提供高质量的临床试验服务。 Novotech持之以恒地致力于打造卓越的职场。在过去的 12 个月中,我们专注于多个领域,包括职场弹性、信息透明度、性别平等、职业发展和我们的实体环境。 为进一步验证我们的工作,在 2 月份,我们还获得了享有盛誉的 WGEA 性别平等最佳雇主奖。 在过去的 12 个月中,受生物技术客户对经验丰富的区域 CRO 的需求的推动,Novotech在亚太地区的员工人数增长了...

Novotech榮膺全球職場文化權威機構認證的“2020 年最佳職場”稱號

亞太地區領先的生物技術委託研究機構CRO Novotech被領先的職場文化機構卓越職場(R)研究所(The Great Place to Work(R) Institute) 認證為“2020 年最佳職場”。這項殊榮是在通過包括文化評估和員工調查在內的全面評估之後授予的。 在獲得認證後,Novotech首席執行官 John Moller 博士說: “這項最佳職場獎對我們而言舉足輕重,它是對我們在人員和文化議程上所做的巨大投資的認可。Novotech團隊在為數眾多的不同地區、文化和語言環境中工作,為我們的生物技術客戶提供高質量的臨床試驗服務。 Novotech持之以恆地致力於打造卓越的職場。在過去的 12 個月中,我們專注於多個領域,包括職場彈性、信息透明度、性別平等、職業發展和我們的實體環境。 為進一步驗證我們的工作,在 2 月份,我們還獲得了享有盛譽的 WGEA 性別平等最佳雇主獎。 在過去的 12 個月中,受生物技術客戶對經驗豐富的區域 CRO 的需求的推動,Novotech在亞太地區的員工人數增長了 20% 以上。 自從發生...

Impact Biomedical initiates Quantum Research Program to solve the Patent Cliff

SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve...

Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext...

Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focusing on the development of novel therapeutics to address global unmet medical needs, today...

Epazz DeskFlex Desk and Room Scheduling System Automates Desk Sanitation as Preventive Measures to...

Desk Scheduling System Helps Prevent the Onset of COVID-19 Infection in the Workplace with its Automatic Scheduling of Cleaning NEWMEDIAWIRE - Epazz, Inc. DeskFlex (OTC: EPAZ),...

MP Biomedicals and A*STAR Co-Develop Rapid Antibody Point-of-care Test Kit for SARS-CoV-2

MP Biomedicals Asia Pacific Pte Ltd, a diagnostic corporation which has been operating for over 30 years focusing on various infectious disease testing development...

SinoMab entered into Strategic Collaboration with D2M

SinoMab BioScience Limited ("SinoMab" of the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of...

Dorsett Hospitality International partners with Prenetics to provide government-recognised Covid-19 testing to combat the...

- All hotels will offer COVID-19 tests for just HK$785 As part of Dorsett Hospitality International's ongoing commitment to the local community under #DorsettCares, the Hong...